Abstract
Current atrial fibrillation (AF) guidelines recommend only amiodarone or dronedarone as antiarrhythmic drugs (AAD) in patients with left ventricular hypertrophy (LVH), due to a postulated pro-arrhythmic risk. However, there are limited clinical data to support these recommendations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
